Related Experiment Video
Updated: Aug 11, 2026
09:39
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
New assignments for multitasking signal transduction inhibitors
Zhihong Zhang1, Kathryn E Meier
1Department of Pharmaceutical Sciences, P.O. Box 646534, Washington State University, Pullman, WA 99164-6534, USA.
Molecular Pharmacology
|February 25, 2006
Summary
Dasatinib, a tyrosine kinase inhibitor, shows potent inhibition of platelet-derived growth factor receptor (PDGFR) and Src kinase. This multi-target action may offer new therapeutic strategies for vascular obstructive diseases.
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Background:
- Tyrosine kinase inhibitors (TKIs) like imatinib are established treatments for chronic myelogenous leukemia.
- TKIs target key signaling pathways, including Bcr-Abl and platelet-derived growth factor receptor (PDGFR).
- PDGFR has not been a primary therapeutic target for TKIs until recently.
Discussion:
- Dasatinib (BMS-354825) is a potent inhibitor of PDGFR and also targets Src kinase.
- This dual inhibition profile contrasts with imatinib's primary Bcr-Abl focus.
- The study by Chen and colleagues highlights dasatinib's unique pharmacological action.
Key Insights:
- Dasatinib exhibits significant inhibitory activity against PDGFR.
- The compound's ability to target both PDGFR and Src kinase is a key finding.
- Multi-target TKIs may offer broader therapeutic benefits.
Outlook:
- The combination of PDGFR and Src kinase inhibition by dasatinib suggests potential applications in treating vascular obstructive diseases.
- This research exemplifies how drugs with multiple molecular targets can yield beneficial therapeutic outcomes.
- Further investigation into multi-target TKIs could expand treatment options for various conditions.
